The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

The Relationship Between Hepatitis C and Vascular Disease

Back to News Homepage

Next

HCV Trial Begins for New Immune Drug

Medivir AB and Tibotec Partner Up To Develop Hepatitis C Polymerase Drug

October 22, 2009

Print this page

By focusing in on HCV polymerase NS5B, two companies join forces to develop new and effective medications for inhibiting the Hepatitis C virus.

Medivir AB Broadens Its Hepatitis C Collaboration with Tibotec, Entering a Partnership in the Field of HCV Polymerase

Regulatory News:

Medivir AB (STO:MVIRB) announced today a new Research, Development and License agreement in the field of hepatitis C virus (HCV). Under the agreement, executed with Ortho Biotech Products L.P. of Bridgewater, NJ (a wholly owned subsidiary of Johnson & Johnson), Medivir will partner with Tibotec BVBA of Mechelen, Belgium.

The goal of the HCV partnership is to identify and develop orally active inhibitors of the HCV polymerase NS5B. Activities will centre on screening new and existing libraries of nucleoside analogues, developed by Medivir, that show anti-HCV activity in vitro.

Read the entire article:
http://www.chiroeco.com/chiropractic/news/4114/44/Medivir-AB-Broadens-Its-Hepatitis-C-Collaboration-with-TibotecEntering-a-Partnership-in-the-Field-of-HCV-Polymerase/

No Comments - be the first!
Share
Share

Previous

The Relationship Between Hepatitis C and Vascular Disease

Back to News Homepage

Next

HCV Trial Begins for New Immune Drug

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.